AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER

被引：0
|
作者：
Gerardi, C. [1 ]
Floriani, I. [1 ]
Biagioli, E. [1 ]
D'Incalci, M. [1 ]
Fossati, R. [1 ]
Colombo, N. [2 ]
机构：
[1] IRCCS Ist Ric Farmacol Mario Negri Milano, Milan, Italy
[2] Univ Milano Bicocca, Dipartimento Sci Chirurg, Milan, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-1249
引用
收藏
页码：455 / 456
页数：2
相关论文
共 50 条
  • [21] A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Alvarez-Secord, A.
    Berchuck, A.
    Higgins, R.
    Nycum, L.
    Kohler, M.
    Puls, L.
    Holloway, R.
    Lewandowski, G.
    Valea, F.
    Havrilesky, L.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S3 - S3
  • [22] EXTENDING THE PLATINUM-FREE INTERVAL (PFI) WITH TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN A PATIENT WITH PARTIALLY PLATINUM-SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC)
    Giovannoni, S.
    Marchetti, C.
    Verkhovskaia, S.
    De Benedetto, A.
    Cortesi, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1357 - 1357
  • [23] Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
    Coleman, Robert L.
    Brady, Mark F.
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Walker, Joan L.
    Kim, Byoung-Gie
    Fujiwara, Keiichi
    Tewari, Krishnansu S.
    O'Malley, David M.
    Davidson, Susan A.
    Rubin, Stephen C.
    DiSilvestro, Paul
    Basen-Engquist, Karen
    Huang, Helen
    Chan, John K.
    Spirtos, Nick M.
    Ashfaq, Raheela
    Mannel, Robert S.
    LANCET ONCOLOGY, 2017, 18 (06): : 779 - 791
  • [24] Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
    Loverix, L.
    Vanderstichele, A.
    Olbrecht, S.
    Van Niewenhuysen, E.
    Van Gorp, T.
    Han, S. N.
    Salihi, R.
    Concin, N.
    Neven, P.
    Busschaert, P.
    Lambrechts, D.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 17 - 18
  • [25] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
  • [26] An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
    Li, Ning
    Bu, Hualei
    Liu, Jihong
    Zhu, Jianqing
    Zhou, Qi
    Wang, Li
    Yin, Rutie
    Wu, Xiaohua
    Yao, Shuzhong
    Gu, Kangsheng
    Zhang, Hui
    Li, Guiling
    Pan, Hongming
    Wu, Qiang
    An, Ruifang
    Yang, Xinfeng
    Zhu, Yaping
    Wan, Xiaoping
    Duan, Wei
    Xiong, Jianping
    Guo, Hongyan
    Lou, Ge
    Wang, Jing
    Hu, Wenjing
    Zhang, Xin
    Meng, Yuanguang
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Wu, Lingying
    CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2452 - 2458
  • [27] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    S McMeekin
    R Patel
    C Verschraegen
    P Celano
    J Burke
    S Plaxe
    P Ghatage
    M Giurescu
    C Stredder
    Y Wang
    T Schmelter
    British Journal of Cancer, 2012, 106 : 70 - 76
  • [28] PHASE I/II STUDY OF SAGOPILONE (ZK-EPO) PLUS CARBOPLATIN IN WOMEN WITH RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J.
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 211 - 211
  • [29] A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)
    Hiroyuki Fujiwara
    Kimio Ushijima
    Shoji Nagao
    Yuji Takei
    Muneaki Shimada
    Masashi Takano
    Kiyoshi Yoshino
    Yoshiaki Kawano
    Yasuyuki Hirashima
    Satoru Nagase
    Shin Nishio
    Tadaaki Nishikawa
    Kimihiko Ito
    Tadahiro Shoji
    Eizo Kimura
    Tadao Takano
    Toru Sugiyama
    Junzo Kigawa
    Keiichi Fujiwara
    Mitsuaki Suzuki
    International Journal of Clinical Oncology, 2019, 24 : 1284 - 1291
  • [30] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Koensgen, Dominique
    Stengel, Dirk
    Belau, Antje
    Klare, Peter
    Oskay-Oezcelik, Guelten
    Steck, Thomas
    Camara, Oumar
    Mustea, Alexander
    Sommer, Harald
    Coumbos, Alexandra
    Bogenrieder, Thomas
    Lichtenegger, Werner
    Sehouli, Jalid
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 393 - 400
12345